宁波市企业投资项目核准办法
浙江省宁波市人民政府
宁波市企业投资项目核准办法
宁波市人民政府令第126号
《宁波市企业投资项目核准办法》已经2005年2月23日市人民政府第38次常务会议审议通过，现予发布，自2005年4月15日起施行。
市长毛光烈
二○○五年三月十一日
第一章 总则
第一条 为规范企业投资项目核准，推动投资体制改革，根据《中华人民共和国行政许可法》、《国务院关于投资体制改革的决定》（国发〔2004〕20号）和国家发展和改革委员会《企业投资项目核准暂行办法》，结合本市实际，制定本办法。
第二条 在本市行政区域内企业投资项目的核准，适用本办法。
本办法所称的企业投资项目是指国内企业不使用政府性资金投资建设的重大和限制类固定资产投资项目。
第三条 市人民政府根据国务院发布的《政府核准的投资项目目录》制定并发布《宁波市、县（市）、区政府核准的投资项目目录》，明确实行核准制的投资项目的范围，划分市、县（市）、区政府的核准权限，并根据经济运行情况和宏观调控需要适时予以调整。
第四条 实行核准制的投资项目, 投资人应当按照本办法的规定办理核准手续并按核准的内容进行项目建设。
第五条 本市企业投资项目的核准由市、县（市）、区发展计划行政主管部门负责，其中企业技术改造投资项目核准由市、县（市）、区工业经济行政主管部门负责。
市、县（市）、区发展计划行政主管部门和工业经济行政主管部门统称政府投资主管部门。
规划、国土资源、环境保护、海洋、金融、安全生产等行政主管部门，应当按照各自职责依法做好企业投资项目的管理工作。
第六条 宁波经济技术开发区管理委员会、宁波大榭开发区管理委员会、宁波保税区管理委员会、宁波市科技园区管理委员会按照县（市）、区政府的权限履行企业投资项目核准职责。
第七条 政府投资主管部门和有关行政管理部门应当加强工作联系和沟通，共享有关管理信息，为投资人申请项目核准提供便利。
第二章 核准程序
第八条 市、县（市）、区政府投资主管部门按照市人民政府颁布的《宁波市、县（市）、区政府核准的投资项目目录》中规定的核准权限，分别对企业投资项目履行核准职责。
核准权限在市政府投资主管部门的项目,项目申请报告可由县(市)、区政府投资主管部门转报。
第九条 应由国务院投资主管部门核准的企业投资项目，由市政府投资主管部门进行初审并提出意见，报国务院投资主管部门核准；应由国务院投资主管部门核准的中央管理企业、计划单列企业集团、国务院行业主管部门隶属单位的投资项目，可直接报国务院投资主管部门核准，但应附上市政府投资主管部门的意见。
第十条 项目核准按下列程序依次进行：
（一）土地、规划、环保等法律、法规有相应规范要求的项目，项目申请人可以先向政府投资主管部门咨询并提交项目概况说明；政府投资主管部门受理咨询并提出咨询意见，抄送相关行政主管部门，并可应项目申请人的要求召集相关行政主管部门对申报项目提出初步意见；
（二）项目申请人凭项目咨询意见办理本办法第十六条规定的文件；
（三）项目申请人按要求向政府投资主管部门提交项目申请报告，并附本办法第十六条规定的文件；
（四）政府投资主管部门出具核准文件，并抄送相关行政主管部门；
（五）项目申请人凭核准文件办理土地使用、资源利用、城市规划、安全生产、设备进口和减免税确认等方面的手续。
对不需要向政府投资主管部门咨询的项目，项目申请人可直接向政府投资主管部门提交项目申请报告和本办法第十六条规定的文件。
第十一条 项目申请人向政府投资主管部门进行项目咨询的，项目申请报告与项目咨询登记表中所陈述的行业属性、产品名称应当一致，且两者所陈述的总投资、建设规模相差不得超过10%。
项目申请报告与项目咨询登记表中所陈述的行业属性、产品名称不一致的，或者两者所陈述的总投资、建设规模相差超过10%的，原项目咨询意见无效。
第十二条 政府投资主管部门经审查决定不予核准的项目，应当作出不予核准的决定，说明理由，并抄送相关行政主管部门。
第十三条 项目核准后，应项目申请人的要求，政府投资主管部门可以组织有关行政主管部门进行项目初步设计会审。
第三章 项目概况说明和项目申请报告
第十四条 项目概况说明应当包括下列内容：
（一）项目申请人的基本情况；
（二）项目的行业属性、产品名称、生产规模、项目投资总额、项目建设内容；
（三）资源和能源耗用情况；
（四）生态环境影响分析。
第十五条 项目申请报告应当包括下列内容：
（一）项目申请人基本情况；
（二）拟建项目基本情况；
（三）建设用地与相关规划；
（四）进口设备与生产工艺流程；
（五）资源利用和能源耗用分析；
（六）生态环境影响分析；
（七）经济和社会效果分析。
项目申请人应向项目核准机关提交项目申请报告一式5份。
第十六条 项目申请人在报送项目申请报告时应当同时提交下列文件：
（一）国土资源行政主管部门的用地预审意见；
（二）规划行政主管部门的规划意见；
（三）环境保护行政主管部门对环境影响评价文件的审批意见；
（四）其他有关法律、法规规定应当提交的文件。
第十七条 报国务院投资主管部门核准的项目，其项目申请报告应由具有甲级工程咨询资格的机构编制；报市政府投资主管部门核准的项目，其项目申请报告应由具有法定工程咨询资格的机构编制。
第四章 核准时限
第十八条 项目申请人按要求上报材料后，政府投资主管部门经过审查认为符合相关要求的，应当予以受理，并向项目申请人出具受理通知书；对不予受理的，应当出具不予受理通知书。
对项目申报材料不齐全或者不符合有关要求的，政府投资主管部门应在收到项目申请报告之日起3个工作日内一次性告知项目申请人，要求项目申请人澄清、补充相关情况和文件，或者对相关内容进行调整。
第十九条 政府投资主管部门在受理申请后认为需要有关咨询机构进行评估的，应当在3个工作日内委托具有法定资格（资质）的咨询机构进行评估。
接受委托的咨询机构应在政府投资主管部门规定的时间内提出评估报告，并对评估结论承担责任。咨询机构在进行评估时可要求项目申请人就有关问题进行说明。
第二十条 政府投资主管部门在进行核准审查时，对涉及其他行政主管部门职能的事项，应征求相关行政主管部门的意见。
相关行政主管部门应在收到征求意见函及附具的项目申请报告后5个工作日内，向政府投资主管部门提出书面审核意见；逾期未反馈书面审核意见的，视为同意政府投资主管部门的意见。
第二十一条 对于可能会对公众利益造成重大影响的项目，政府投资主管部门在进行核准审查时应当征求公众意见，并通过适当方式向公众反馈。对于特别重大的项目，可以实行专家评议制度。
第二十二条 政府投资主管部门应在受理项目申请报告之日起15个工作日内,作出对项目申请是否核准的决定，或向上级项目核准机关提出审核意见。由于情况复杂难以在15个工作日内作出核准决定的，经本机关负责人批准，可以延长7个工作日，并应及时书面通知项目申请人，说明延期理由。
政府投资主管部门委托咨询机构评估、征求公众意见和进行专家评议的，所需时间不计算在前款规定的期限内。
第五章 核准条件、效力和监督
第二十三条 政府投资主管部门根据下列条件对项目进行审查：
（一）符合有关法律、法规、规章的规定；
（二）符合国民经济和社会发展规划、行业规划、产业政策、行业准入标准和土地利用总体规划；
（三）符合国家宏观调控政策；
（四）地区布局合理；
（五）主要产品未对国内市场形成垄断；
（六）未影响经济安全；
（七）合理开发并有效利用资源；
（八）生态环境和自然文化遗产得到有效保护；
（九）未对公众利益，特别是项目建设地的公众利益产生重大不利影响。
第二十四条 项目核准文件有效期为2年，自作出核准决定之日起计算。
项目在核准文件有效期内未开工建设的，项目申请人应在核准文件有效期届满30日前向政府投资主管部门申请延期。政府投资主管部门接到延期申请后应在核准文件有效期届满前作出是否准予延期的决定。
项目在核准文件有效期内未开工建设且项目申请人未向政府投资主管部门申请延期的，该项目核准文件自行失效。
第二十五条 已经核准的项目，如需对项目核准文件所规定的内容进行调整的，项目单位应及时以书面形式向政府投资主管部门报告。政府投资主管部门应根据项目调整的具体情况，出具书面确认意见或要求其重新办理核准手续。
第二十六条 有下列情形之一的，政府投资主管部门可以注销项目核准：
（一）项目核准后两年内未开工建设的；
（二）项目申请人的主体资格依法终止的；
（三）法律、法规规定的应当注销的其他情形。
第二十七条 禁止项目申请人以拆分项目、提供虚假材料等方式申请核准。
第二十八条 已经核准的项目，项目申请人应当按有关规定定期向政府投资主管部门报送项目进度表，项目完工后应当向政府投资主管部门报送项目完工情况表。
第二十九条 政府投资主管部门应当对项目申请人、工程咨询机构和评估机构在投资项目申请和项目建设中的信用情况进行监督，对其不良信用情况予以记录，并向企业信用管理部门通报。
第三十条 对应报政府投资主管部门核准而未申报，或者虽然申报但未经核准的项目，国土资源、环境保护、规划、质量、证券、外汇、安全生产、水资源、海关等行政主管部门不得办理相关手续，金融机构不得发放贷款。
第三十一条 市政府投资主管部门应当每年定期对各县（市）、区政府及宁波经济技术开发区、宁波大榭开发区、宁波保税区、宁波市科技园区的项目核准工作进行监督检查，并逐步建立项目管理数据库。
第六章 法律责任
第三十二条 违反本办法第四条的规定，未办理核准手续或未按核准的内容进行项目建设的，政府投资主管部门应当立即责令其停止建设，并按照有关法律、行政法规的规定予以处理。
第三十三条 违反本办法第二十七条规定，项目申请人以拆分项目、提供虚假材料等方式获得核准的，政府投资主管部门应当撤销核准，责令其停止建设，并依法追究有关责任人的责任。
第三十四条 政府投资主管部门工作人员，在项目核准过程中滥用职权、玩忽职守、徇私舞弊、索贿受贿的，依法给予行政处分；构成犯罪的，依法追究刑事责任。
第三十五条 工程咨询机构、评估机构及其工作人员，在咨询、评估过程中违反职业道德、造成重大损失和恶劣影响的，依法追究相应责任。
第七章 附 则
第三十六条 非企业组织、个人投资建设《宁波市、县（市）、区政府核准的投资项目目录》范围内的项目，按照本办法予以核准。
第三十七条 本市外商投资项目、境外投资项目的核准，按照有关规定执行。
第三十八条 本办法自2005年4月15日起施行。
Provisions for Drug Advertisement Examination
State Food and Drug Administration，State Administration for Industry and Commerceof the People’s Republic of China
Provisions for Drug Advertisement Examination
(SFDA Decree No. 27)
The Provisions for Drug Advertisement Examination, adopted by the State Food and Drug Administration and the State Administration for Industry and Commerce of the People’s Republic of China, is now issued in the decree sequence number of the State Food and Drug Administration. The Provisions shall go into effect as of the date of May 1, 2007.
Shao Mingli
Commissioner
State Food and Drug Administration
Zhou Bohua
Minister
State Administration for Industry and Commerceof the People’s Republic of China
March 13, 2007
Provisions for Drug Advertisement Examination
Article 1 The Provisions are formulated for the purposes of strengthening regulation on drug advertisements and ensuring the authenticity and legality of drug advertisements in accordance with the Advertisement Law of the People’s Republic of China (hereinafter referred to as Advertisement Law), the Drug Administration Law of the People's Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for the Implementation of Drug Administration Law of the People's Republic of China (hereinafter referred to as Regulations for the Implementation of Drug Administration Law) and other regulations related to supervision on advertisements and drugs.
Article 2 A drug advertisement refers to any advertisement published through various media or forms containing drug name, indications (functions) or other relevant contents, and shall be examined and approved in accordance with the Provisions.
Where only the names of non-prescription drugs (including adopted names and trade names) are publicized or only the names of prescription drugs (including adopted names and trade names) are publicized in professional medical or pharmaceutical journals, the examination is not required.
Article 3 The drug advertisement applied for examination shall be approved provided that it conforms to the following laws, regulations and related provisions:
(1) Advertisement Law;
(2) Drug Administration Law;
(3) Regulations for Implementation of Drug Administration Law;
(4) Criteria for Examining and Publishing Drug Advertisement;
(5) Other provisions of the State on advertisement regulation.
Article 4 The drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government are the drug advertisement examination authorities responsible for examining drug advertisements within their administrative regions. The administrative departments for industry and commerce at or above the county level are supervision and control authorities for drug advertisements.
Article 5 The State Food and Drug Administration shall guide and supervise the examination conducted by drug advertisement examination authorities and punish, in accordance with law, the examination authorities that have violated the Provisions.
Article 6 An applicant for a drug advertisement approval number must be an eligible drug manufacturer or distributor. Where the applicant is a drug distributor, the consent of the drug manufacturer is required.
An applicant may entrust an agent with the application for a drug advertisement approval number.
Article 7 An application for a drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the drug manufacturer is located.
An application for an import drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the agent of the import drug is located.
Article 8 Where a drug manufacturer or distributor applies for a drug advertisement approval number, it shall submit an Application Form for Drug Advertisement (Appendix 1) with sample manuscript (sample film or sample record) of which the content is consistent with that to be published attached, and an electronic document of drug advertisement application. It shall also submit the following proof documents that are authentic, legal and valid:
(1) Copy of the Business License of the applicant;
(2) Copy of the Drug Manufacturing Certificate or the Drug Supply Certificate of the applicant;
(3) Where the applicant is a drug distributor, the original document proving that the drug manufacturer authorizes the drug distributor to be the applicant shall be submitted;
(4) Where an agent submits an application for a drug advertisement approval number on behalf of the applicant, an original authorization letter given by the applicant to the agent, a copy of business license of the agent and other documents proving the subject’s qualifications shall be submitted;
(5) Copies of the drug approval document (including Import Drug License or Pharmaceutical Product License), copy of approved insert sheet, and label and insert sheet used in practice;
(6) For non-prescription drug advertisement, a copy of registration certificate of non-prescription drug examination or copies of relevant certificates is required;
(7) Where an applicant applies for an import drug advertisement approval number, copies of qualification certificates of the agent of the import drug shall be submitted;
(8) Where the trade name, registered trademark and patent of the drug are involved in an advertisement, copies of the valid certificates and other relevant documents proving the authenticity of the advertisement shall be submitted.
The copy of any approval document prescribed in this Article shall be sealed by the document holder.
Article 9 An advertisement application by an enterprise for a drug shall not be accepted by the drug advertisement examination authorities under any of the following circumstances:
(1) Any of the circumstances under which the application shall be rejected as prescribed in Article 20, Article 22 and Article 23 of the Provisions;
(2) An administrative procedure to withdraw a drug advertisement approval number is in process.
Article 10 After receiving an application for drug advertisement approval number, where the dossier is complete and in conformity with statutory requirements, the drug advertisement examination authority shall issue an Acceptance Notice of Drug Advertisement; where the dossier is incomplete or not conforming to the statutory requirements, one notification on all the content to be supplemented or corrected shall be given to the applicant on the spot or within five working days; if the notification to the applicant is not issued within the timeline, the application is deemed as being accepted upon the date when the dossier is received.
Article 11 Within ten working days upon accepting an application, the drug advertisement examination authority shall check the authenticity, legality and validity of the documents submitted by the applicant, and shall examine the advertisement content in accordance with law. For the drug advertisement in conformity with statutory requirements, a drug advertisement approval number shall be issued; for those not in conformity with statutory requirements, the authority shall make a decision of not issuing a drug advertisement approval number and notify the applicant of the decision with reasons in written form and the applicant’s right to apply for administrative reconsideration or to bring an administrative suit by law.
For approved drug advertisement, the drug advertisement examination authority shall report to the State Food and Drug Administration for records and send the approved Application Form for Drug Advertisement to the authority responsible for advertisement supervision and control at the same level for records. Where there is any problem in the drug advertisement reported to the State Food and Drug Administration for records, the State Food and Drug Administration shall instruct the drug advertisement examination authority to correct it.
The drug regulatory departments shall announce the approved drug advertisement timely.
Article 12 Where a drug advertisement is to be published in the province, autonomous region or municipality directly under the Central Government other than the place where the drug manufacturer and the agent of the import drug are located (hereinafter referred to as “non-local drug advertisement”), it shall, before being published, be submitted for records to the drug advertisement examination authority in the place where the advertisement is to be published.
Article 13 The following materials for non-local drug advertisement shall be submitted for record:
(1) Copy of the Application Form for Drug Advertisement;
(2) Copy of the approved drug insert sheet;
(3) For television or audio broadcast advertisement, it is required to submit the audio tape, compact disc or other medium carrier on which the content is consistent with the approved content.
The copy of any document prescribed in this Article shall be sealed by the document holder.
Article 14 For application for putting non-local drug advertisement on record in accordance with Articles 12 and Article 13 of the Provisions, the drug advertisement examination authority shall, within five working days after accepting the application, put such drug advertisement on record, endorse the word “recorded” on the Application Form for Drug Advertisement, affix the seal specific for drug advertisement examination and send the form to the supervision and control authorities for advertisements at the same level for future reference.
Where the drug advertisement examination authority of a place where a drug advertisement is to be put on record finds that the drug advertisement is not conformed with the relevant provisions, it shall fill in the Opinion on the Record of Drug Advertisement Examination (Appendix 2), submit it to the original drug advertisement examination authority for check, and copy it to the State Food and Drug Administration.
Within five working days upon receiving the Opinion on the Record of Drug Advertisement Examination, the original drug advertisement examination authority shall give its opinions to the drug advertisement examination authority of the place where the drug advertisement is to be put on record. Where no consensus is achieved between the original drug advertisement examination authority and the drug advertisement examination authority of the place where a drug advertisement is to be put on record, the case may be submitted to the State Food and Drug Administration that shall make a final judgment.
Article 15 The valid term of a drug advertisement approval number is one year. It shall become invalid upon expiration.
Article 16 The content of an approved drug advertisement is not allowed to be changed when being published. Where any change to the drug advertisement is needed, a new drug advertisement approval number shall be obtained.
Article 17 Where an advertisement applicant publishes a drug advertisement by itself, it shall keep the original Application Form for Drug Advertisement for two years for future check.
Where an advertisement publisher or advertising operator is authorized by the applicant to publish a drug advertisement, it shall check the original Application Form for Drug Advertisement, publish the advertisement in accordance with the approved content and keep a copy of the Applicant Form for Drug Advertisement for two years for future check.
Article 18 Where there is any of the following circumstances for an approved drug advertisement, the original drug advertisement examination authority shall issue a Notice of Drug Advertisement Re-examination (Appendix 3) and conduct the re-examination. The drug advertisement may continue to be published during the re-examination.
(1) The State Food and Drug Administration finds that the content of the drug advertisement approved by the drug advertisement examination authority is not in conformity with the provisions;
(2) A supervision and control authority for advertisement at or above provincial level makes a re-examination proposal;
(3) Other circumstances where a re-examination is required by a drug advertisement examination authority.
After re-examination, where the drug advertisement is not in conformity to the statutory requirements, the Application Form for Drug Advertisement shall be taken back and the original drug advertisement approval number shall become invalid.
Article 19 Drug advertisement examination authorities shall cancel the drug advertisement approval number in any of the following circumstances:
(1) Where a Drug Manufacturing Certificate or the Drug Supply Certificate is revoked;
(2) Where a drug approval document is withdrawn or cancelled;
(3) Where the State Food and Drug Administration or the drug regulatory department of the province, autonomous region or municipality directly under the Central Government instructs to stop the production, sales and use of the drug.
Article 20 For any alteration to the approved content of a drug advertisement for false propaganda, the drug regulatory departments shall instruct to stop the publication of the advertisement immediately, revoke the drug advertisement approval number, and shall not accept any application for advertisement of the drug within one year.
Article 21 Where any illegal advertisement in which the scope of indications (functions) of the drug is expanded without authorization, the therapeutic effectiveness is exaggerated extremely, or which seriously cheats or misleads the customers, is found, the drug regulatory department at or above the provincial level shall take mandatory administrative measures to suspend the sales of the drug within their administrative area and order the enterprise that illegally publishes the drug advertisement to issue a correction notice in relevant local media.
After the enterprise that illegally publishes the drug advertisement issues a correction notice as required, the drug regulatory department at or above the provincial level shall make a decision on lifting the mandatory administrative measures within 15 working days; where it is necessary to test the drug, the drug regulatory departments shall determine whether to lift the mandatory administrative measures within 15 days as from the day when the test report is issued.
Article 22 Where a drug advertisement application providing false materials is found by the drug advertisement examination authority during the examination, no further application of the enterprise in respect of the advertisement of the drug shall be accepted within one year.
Article 23 Where a drug advertisement with an approval number is found by the drug advertisement examination authority to have provided false materials, such drug advertisement approval number shall be revoked and no further application from the enterprise in respect of the advertisement of the drug shall be accepted within three years.
Article 24 Any drug advertisement, of which the approval number is taken back, cancelled or revoked in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, shall be discontinued for publication immediately; non-local drug advertisement examination authorities shall stop filing the record of the advertisement of the enterprise with the drug advertisement approval number.
Where a drug advertisement examination authority takes back, cancels or withdraws a drug advertisement approval number in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, it shall notify the supervision and control authority for advertisements at the same level within five working days from the day when the administrative decision on the matter is made; the supervision and control authority for advertisements shall handle it in accordance with law.
Article 25 Where a non-local drug advertisement is found not put on record in the drug advertisement examination authority of the place where it is published, the authority shall instruct to file its record within a time limit. If the record is not filed within the time limit, the drug advertisement in the above-mentioned place shall be suspended.
Article 26 The drug regulatory department at or above the county level shall monitor and check the publishing of drug advertisement that has been examined and approved. For any illegal drug advertisements, drug regulatory departments at all levels shall fill in the Notice on the Transfer of Illegal Drug Advertisement (Appendix 4) and transfer it to an supervision and control authority for advertisements at the same level together with such materials as samples of illegal drug advertisement; where the content of approved non-local drug advertisement is altered without permission, the drug advertisement examination authority of the place where the advertisement is published shall advise the original drug advertisement examination authority to revoke its approval number in accordance with Article 92 of the Drug Administration Law and Article 20 of the Provisions.
Article 27 Where an illegal drug advertisement is published and the circumstances are serious, the drug regulatory department of province, autonomous region or municipality directly under the Central Government shall announce the matter to the public and timely report it to the State Food and Drug Administration. The State Food and Drug Administration shall summarize and release the collected information periodically.
Where any false or illegal drug advertisement is published and the circumstances are serious, it shall be announced to the public jointly by the State Administration for Industry and Commerce and the State Food and Drug Administration if necessary.
Article 28 For any drug advertisement published without approval, or the contents published inconsistent with the approved ones, the supervision and control authority for advertisements shall impose a punishment in accordance with Article 43 of the Advertisement Law; where it constitutes false advertisement or misleading propaganda, the supervision and control authorities for advertisements shall impose a punishment in accordance with Article 37 of the Advertisement Law and Article 24 of Anti-Unfair Competitions Law.
In the process of investigation of an illegal drug advertisement, where there is a need to affirm any drug technical information, the supervision and control authority for advertisements shall notify the drug regulatory department at or above the provincial level. The drug regulatory department at or above the provincial level shall give the affirmation result to the supervision and control authorities for advertisements within ten working days after receiving the notification.
Article 29 The staff members that examine and supervise drug advertisements shall be trained in such laws and regulations as the Advertisement Law and the Drug Administration Law. Where the staff members in drug advertisement examination department or in supervision and control authority for drug advertisements neglect their duty, abuse their power, or practice favoritism and commit irregularities, they shall be given an administrative sanction in accordance with law. If a crime is constituted, they shall be investigated for their criminal liabilities in accordance with law.
Article 30 A drug advertisement approval number shall be “X Yao Guang Shen (Shi) No. 0000000000", “X Yao Guang Shen (Sheng) No. 0000000000", “X Yao Guang Shen (Wen) No. 0000000000". “X” is the abbreviation for a province, autonomous region or municipality directly under the Central Government. “0000000000” is a number with ten digits, in which the first six represent year and month of the examination, and the last four represent advertisement approval sequence number. “Shi”, “Sheng” or “Wen” represents certain classification code used in advertising media.
Article 31 These Provisions shall come into force as of May 1, 2007. The Provisions for Drug Advertisement Examination issued by the State Administration for Industry and Commerce and the Ministry of Health (Decree of State Administration for Industry and Commerce No. 25) on March 22, 1995 shall be annulled therefrom.